Citius Oncology, Inc. CTOR License Payable
License Payable at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept ctor:LicensePayable.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s license payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s license payable?
- Citius Oncology, Inc. (CTOR) reported license payable of $17.65M in Q1 2026.
- How has Citius Oncology, Inc.'s license payable changed year-over-year?
- Citius Oncology, Inc.'s license payable decreased by 37.9% year-over-year, from $28.4M to $17.65M.
- What does license payable mean?
- The total amount of obligations due within one year related to the acquisition of intellectual property or licensing rights for pharmaceutical products. This liability reflects the company's contractual commitments to pay licensors for the right to develop or commercialize specific compounds. Monitoring this helps assess near-term cash flow requirements and the cost structure of the product pipeline.